LCAT Genotype

Your HDL number on a routine cholesterol panel tells you how much good cholesterol is in your blood. It does not tell you why. For a small but meaningful group of people, a glitch in a single gene called LCAT (lecithin cholesterol acyltransferase) is the reason HDL runs low, and that same glitch can quietly drive kidney trouble, corneal clouding, and in some cases earlier heart disease.

This test reads the gene that builds the LCAT enzyme, the workhorse that loads cholesterol into HDL particles so your body can clear it. Knowing your variant explains an unexplained low HDL, flags conditions that standard lipid panels miss, and gives biological family members a chance to learn whether they carry the same risk.

What LCAT Actually Does

LCAT is an enzyme in your bloodstream that takes cholesterol floating on the surface of HDL particles and converts it into a storage form, allowing HDL to mature from small disc shaped particles into larger spherical ones that can ferry cholesterol away to the liver. When the gene that builds this enzyme carries a damaging variant, HDL particles cannot mature properly. The result shows up on a lipid panel as low HDL cholesterol, often dramatically low, and on other tests as unusual lipoprotein shapes and sizes.

Variants in LCAT fall on a spectrum. On one end are rare, severe mutations that cause familial LCAT deficiency (FLD), a near total loss of enzyme function on both HDL and LDL-like particles. Slightly less severe variants cause fish eye disease (FED), where the enzyme still works on LDL-like particles but loses activity on HDL. On the other end are common single letter changes that subtly nudge HDL levels and lipid patterns across the general population. People with FLD also tend to have low LDL cholesterol, which is part of why the heart disease picture is more complicated than low HDL alone would suggest.

How One or Two Bad Copies Changes Your Lipids

You carry two copies of every gene, one from each parent. The number of damaged LCAT copies you inherit determines how much of your lipid biology shifts. In a study of 13 unrelated Italian families carrying 17 different mutations, each added mutant copy produced a step by step rise in raw unesterified cholesterol, VLDL particles, and an immature form of HDL, alongside step by step drops in HDL cholesterol, the proteins that make up HDL, LCAT enzyme activity, and HDL particle size.

People with one mutated copy, called heterozygotes, are not silent carriers. In a multi family study, their LCAT activity ran at roughly half of normal, clearly separable from unaffected relatives. They typically have low but not vanishingly low HDL. People with two mutated copies, called homozygotes, can lose enzyme activity almost completely, with HDL cholesterol that drops into the very low range and full clinical syndromes that follow.

Heart Disease Risk: A Genuine Paradox

The relationship between LCAT variants and heart disease is one of the most counterintuitive stories in lipid genetics. Low HDL is a well known marker of higher heart attack risk in the general population, so you might expect LCAT carriers, who often have very low HDL, to have runaway heart disease. The data are split.

In Italian families with severe LCAT mutations, carriers actually had smaller carotid artery wall thickness than control relatives despite low HDL. The carotid wall ran 0.07 mm thinner in heterozygotes and 0.21 mm thinner in homozygotes compared with controls, and the effect was gene dose dependent. In a separate Dutch group of heterozygotes, the opposite was true. Partial LCAT deficiency, with HDL cholesterol roughly 36 percent lower than controls, came with thicker carotid walls, higher triglycerides, and higher C reactive protein (a marker of inflammation), pointing toward higher atherosclerosis risk.

This split is better explained by the type of LCAT defect than by population alone. A 2018 head to head analysis combining Italian and Dutch carriers found that variants causing complete familial LCAT deficiency (FLD) were linked to less atherosclerosis, while variants causing fish eye disease (FED) were linked to more atherosclerosis. A Mexican kindred review echoed the same pattern, finding that people with fish eye disease had a significantly higher risk of early coronary artery disease compared with classic familial LCAT deficiency. So the practical takeaway is that the specific type of variant, and the lipid environment around it, matters more than the simple presence of low HDL.

In the Egyptian general population, the T allele of a common LCAT polymorphism called rs5923 was associated with premature coronary artery disease, and the effect was strongest in people who also had low HDL. In a Turkish cohort, the T allele was more frequent in people with HDL under 35 mg/dL than in those with HDL over 65 mg/dL, with allele frequencies of 0.54 versus 0.37 in those two groups.

Kidney Disease

For many LCAT carriers, the kidneys are the organ most at risk. In a large family carrying the severe P274S variant, people with two mutated copies showed progressive loss of kidney filtration, anemia, and higher rates of cardiovascular and kidney complications than relatives without two copies. Another follow up of Italian families with familial LCAT deficiency confirmed rapid kidney deterioration in some, with the rate predicted by high plasma unesterified cholesterol levels.

The mutation alone does not seal your fate. People with the same genotype can take very different kidney trajectories. The central driver of kidney injury appears to be an unusual lipid particle called LpX, which builds up when LCAT activity is lost and deposits in the kidney filter, causing progressive damage. Triglyceride rich VLDL particles and high unesterified cholesterol add to the abnormal lipid environment, but LpX is the particle most consistently tied to the kidney damage in both human and animal studies. This is why two siblings with the same homozygous variant can have very different kidney outcomes depending on how much LpX their lipid environment generates.

Corneal Clouding and Anemia

Two visible signs of severe LCAT deficiency are slowly developing cloudiness of the cornea, the clear window at the front of the eye, and chronic anemia (a shortage of healthy red blood cells). A homozygous carrier of a newly described variant called p.Trp315Arg developed corneal opacity caused by amyloid buildup along with severe HDL reduction and anemia. In fish eye disease, two novel variants called p.Asn29Ser and p.Tyr351Cys produced very low HDL and corneal clouding with milder body wide disease.

How Common Are These Variants

Severe LCAT mutations are rare, but they are more common than many clinicians realize in people with otherwise unexplained low HDL. In a Dutch group of 98 people referred for very low HDL cholesterol, 28 of them, or 29 percent, were heterozygous for nonsynonymous LCAT mutations. Because this group was specifically referred for very low HDL, the yield in the general population is much smaller. Still, for someone whose HDL is persistently low without an obvious cause, a genetic LCAT cause is genuinely on the table.

Emerging Treatments

There is no approved drug that fixes a damaged LCAT gene, but research into recombinant human LCAT, a lab made version of the enzyme given by infusion, has shown early promise. In small human and animal studies, recombinant LCAT raised HDL cholesterol, lowered LpX, and improved kidney function markers. These treatments are still investigational and are not part of routine care, but they may change the outlook for severe LCAT deficiency in the coming years.

One Time Result, Lifetime Implications

The LCAT gene you were born with is the gene you will have when you die. The test result does not change, so retesting the genetic marker itself is not the point. The value is in what you do with the answer over the years that follow.

If you carry a damaging variant, the practical tracking moves to the downstream measurements that the variant affects. That means more frequent lipid panels with attention to HDL cholesterol, ApoA1 (a protein that makes up HDL), and triglycerides. It means regular kidney function testing, including estimated GFR (a number that gauges how well your kidneys filter blood) and a urine protein test, because kidney damage can creep in silently. It means a baseline eye exam and periodic monitoring for corneal cloudiness. And it means a complete blood count, since chronic low grade anemia can be the first hint that LCAT related disease is becoming active. A reasonable rhythm is annual lipid and kidney panels at minimum, with closer monitoring if the early signs start to drift.

What to Do With an Unexpected Result

If your LCAT genotype reveals a variant you did not expect, the next steps are about workup, not retesting. The genetic call itself rarely needs to be repeated unless your laboratory flags the variant as uncertain. What changes is the workup that surrounds it.

• Confirm the lipid picture: order a full lipid panel including ApoA1, ApoB (a particle count for the cholesterol that drives heart disease), and a measure of HDL particle size or number to characterize how the variant is affecting your lipids in real time.
• Check kidney and red blood cell function: estimated GFR, urine albumin to creatinine ratio (a sign of early kidney damage), and a complete blood count. A more sensitive filtration marker such as cystatin C may add information, though it is not specifically required by current rare dyslipidemia guidelines. Together these give you a baseline you can track against.
• Get an ophthalmology baseline: a slit lamp eye exam catches early corneal changes before they affect vision.
• Talk to a lipidologist or genetic counselor: the interpretation of any specific LCAT variant depends on what is known about that exact change, your family history, and your other lipid markers. A specialist familiar with rare HDL disorders can help separate variants that need aggressive follow up from variants whose meaning is still uncertain.

What This Means for Your Family

LCAT variants follow standard inheritance patterns. If you carry one damaging copy, each of your biological children has a 50 percent chance of inheriting it. Your siblings each had a 50 percent chance of inheriting the same variant from the same parent. If you carry two damaging copies, both of your parents are at minimum carriers, and your children will all inherit at least one copy.

Cascade testing, the practice of offering the same genetic test to first degree relatives once a variant is identified in one family member, is the highest yield way to find affected relatives. They benefit from the same earlier and more frequent monitoring that you do. Carrying a variant does not guarantee you will develop disease. It raises the odds and sets the pattern of what to watch for.